Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaele Ornello

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
Cephalalgia : an International Journal of Headache|June 5, 2026
Diagnostic tests and headache misdiagnoses in individuals with resistant and refractory migraine - data from the REFINE studyFederico De Santis, Chiara Rosignoli, Agnese Onofri, et al.
Frontiers in Neurology|September 22, 2025
Sex differences in the clinical features of 2,841 patients with migraine: a <i>post-hoc</i>, multicenter, cross-sectional studyMarina Romozzi, Luigi Francesco Iannone, Marcello Silvestro, et al.
The Journal of Headache and Pain|August 15, 2025
Longitudinal assessment of migraine burden in resistant and refractory migraine - Data from the prospective REFINE studyUmberto Pensato, Raffaele Ornello, Chiara Rosignoli, et al.
Frontiers in Neurology|January 3, 2022
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in MenRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|February 20, 2026
Atrial fibrillation detection after Embolic Stroke of Undetermined Source: development and validation of the CATCH-AF scoreLucio D'Anna, Francesco Favruzzo, Claudio Baracchini, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Journal of Neurology|May 15, 2023
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysisAhmed Abdelhak, Lorenzo Barba, Michele Romoli, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|March 25, 2026
Timing of Insertable Cardiac Monitor Implantation After ESUS and Its Impact on Atrial Fibrillation Detection: A Target Trial Emulation AnalysisLucio D'Anna, Fionn Mag Uidhir, Robert Simister, et al.
Cephalalgia : an International Journal of Headache|March 25, 2026
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerabilityLuigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
Cephalalgia : an International Journal of Headache|June 5, 2026
Diagnostic tests and headache misdiagnoses in individuals with resistant and refractory migraine - data from the REFINE studyFederico De Santis, Chiara Rosignoli, Agnese Onofri, et al.
Frontiers in Neurology|September 22, 2025
Sex differences in the clinical features of 2,841 patients with migraine: a <i>post-hoc</i>, multicenter, cross-sectional studyMarina Romozzi, Luigi Francesco Iannone, Marcello Silvestro, et al.
The Journal of Headache and Pain|August 15, 2025
Longitudinal assessment of migraine burden in resistant and refractory migraine - Data from the prospective REFINE studyUmberto Pensato, Raffaele Ornello, Chiara Rosignoli, et al.
Frontiers in Neurology|January 3, 2022
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in MenRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|February 20, 2026
Atrial fibrillation detection after Embolic Stroke of Undetermined Source: development and validation of the CATCH-AF scoreLucio D'Anna, Francesco Favruzzo, Claudio Baracchini, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Journal of Neurology|May 15, 2023
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysisAhmed Abdelhak, Lorenzo Barba, Michele Romoli, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|March 25, 2026
Timing of Insertable Cardiac Monitor Implantation After ESUS and Its Impact on Atrial Fibrillation Detection: A Target Trial Emulation AnalysisLucio D'Anna, Fionn Mag Uidhir, Robert Simister, et al.
Cephalalgia : an International Journal of Headache|March 25, 2026
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerabilityLuigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, et al.
Pageof 19